The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign that ran in the EU, ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...

By the time someone reached me, they had often been on a diagnostic journey for years – misdiagnosed, undertreated, cycling ...

A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with ...